The relationship between insulin resistance and serum adiponectin levels in 400 subjects with different obesity-related diseases was studied. Lean subjects with body mass index (BMI) < 25 kg/m2 were placed in one group and the other five groups of overweight/obese subjects with BMI ≥ 25 kg/m2 were grouped according to disease profile. The homeostasis model assessment insulin resistance (HOMA-IR) index and adiponectin levels were similar in the lean, metabolically normal (MNO) and hypertensive groups, but were different when the dyslipidaemic group was compared with the lean and MNO groups. The type 2 diabetic (DMO) and hypertensive, type 2 diabetic (DMHTO) groups were significantly different from other groups with respect to HOMA-IR index and adiponectin levels. Adiponectin levels were lower in the DMHTO than the DMO group. In multiple regression analysis, adiponectin levels correlated with group categorization independently of age, sex, BMI and HOMA-IR. Hypoadiponectinaemia may play a role in the development of complications of obesity.
ShimomuraIFunahashiTMatsuzawaY: Adipocytokines; cause for metabolic syndrome. Curr Med Chem2003; 3: 121–125.
2.
KarelisADSt-PierreDHConusF: Metabolic and body composition factors in subgroups of obesity: What do we know?J Clin Endocrinol Metab2004; 89: 2569–2575.
3.
von EybenFEMouritsenEHolmJ: Intraabdominal obesity and metabolic risk factors: A study of young adults. Int J Obes Relat Metab Disord2003; 27: 941–949.
4.
MannucciEBardiniGRotellaF: Comparison among different insulin sensitivity indices in obese patients. Diabet Med2003; 20: 462–466.
5.
TaiESLauTNHoSC: Body fat distribution and cardiovascular risk in normal weight women. Association with insulin resistance, lipids and plasma leptin. Int J Obes2000; 24: 751–757.
6.
KershawEEFlierJS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab2004; 89: 2548–2556.
7.
ParkKGParkKSKimMJ: Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract2004; 63: 135–142.
8.
MatsuzawaYShimomuraIKiharaS: Importance of adipocytokines in obesity-related diseases. Horm Res2003; 60 (suppl 3): 56–59.
9.
MatsubaraMKatayoseSMaruokaS: Decreased plasma adiponectin concentrations in nondiabetic women with elevated homeostasis model assessment ratios. Eur J Endocrinol2003; 148: 343–350.
10.
TschritterOFritscheAThamerC: Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes2003; 52: 239–243.
11.
WagnerJALarsonPJWeissS: Individual and combined effects of peroxisome proliferator-activated receptor and gamma agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers. J Clin Pharmacol2005; 45: 504–513.
12.
OseiKGaillardTKaplowJ: Effects of rosiglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism2004; 53: 1552–1557.
13.
YamauchiTKamonJWakiH: Globular adiponectin protected ob/ob mice from diabetes and Apo E-deficient mice from atherosclerosis. J Biol Chem2003; 278: 2461–2468.
14.
AbbasiFChuJWLamendolaC: Discrimination between obesity and insulin resistance in relationship with adiponectin. Diabetes2004; 53: 585–590.
15.
MatsubaraMMaruokaSKatayoseS: Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab2002; 87: 2764–2769.
16.
BarattaRAmatoSDeganoC: Adiponectin relationship with lipid metabolism is independent of body fat mass: Evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab2004; 89: 2665–2671.
17.
HottaKFunahashiTAritaY: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol2000; 20: 1595–1599.
18.
AdamczakMWiecekAFunahashiT: Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens2003; 16: 72–75.
19.
IwashimaYKatsuyaTIshikawaK: Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension2004; 43: 1318–1323.
20.
DzielinskaZJanuszewiczAWiecekA: Decreased plasma concentration of a novel anti-inflammatory protein—adiponectin—in hypertensive men with coronary artery disease. Thromb Res2003; 110: 365–369.
21.
AritaYKiharaSOuchiN: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun1999; 257: 79–83.
22.
RyoMNakamuraTKiharaS: Adiponectin as a biomarker of the metabolic syndrome. Circ J2004; 68: 975–981.
23.
KissebahAHKrakowerGR: Regional adiposity and morbidity. Physiol Rev1994; 74: 761–811.
24.
MatthewsDRHoskerJPRudenskiAS: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia1985; 28: 412–419.
25.
American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care2005; 28: 37–42.
26.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA2001; 285: 2486–2497.
27.
SungKCKimBJKimBS: In normoglycemic Koreans, insulin resistance and adiposity are independently correlated with high blood pressure. Circ J2004; 68: 898–902.
MallamaciFZoccaliCCuzzolaF: Adiponectin in essential hypertension. J Nephrol2002; 15: 507–511.
30.
FuruhashiMUraNHigashiuraK: Blockade of the renin—angiotensin system increases adiponectin concentration in patients with essential hypertension. Hypertension2003; 42: 76–81.
31.
El-AtatFAStasSNMcFarlaneSI: The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol2004; 15: 2816–2827.
32.
PischonTGirmanCJHotamisligilG: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA2004; 291: 1730–1737.
